Thank you to everyone who joined our Rare Disease Day webinar. From gene targeted therapies to accelerated approvals, the inspiring discussion highlighted how patient leadership continues to shape ultra rare disease drug...

Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a...

Antibody-drug conjugates (ADCs) continue to reshape global oncology, yet navigating the evolving regulatory landscape remains a significant challenge. In this new BioSpectrum Asia feature, ICON’s regulatory expert, Eili...

Antibody-drug conjugates are transforming cancer treatment, but their complexity demands a clear and forward-looking regulatory strategy. In this new BioSpectrum Asia article, ICON experts break down the evolving global...

Because rare autoimmune conditions are so complex, vaccine decisions should be approached on an individual basis. Discover key elements of a vaccine schedule framework for patients in this vulnerable population in our ne...

Latest issue out now. Keep up to date on the most recent regulatory changes in the world of pharma, biotech and medical device clinical trials with ICON’s Regulatory Intelligence Newsletter. Join thousands of subscribe...

We're pleased to share highlights of our ongoing CSR initiatives in Chennai. Colleagues from ICON's India team recently joined a Plantation Drive at SOS Children's Village, planting over 50 saplings as part of our ongoi...

On 30 March – 2 April at the World Vaccine Congress, speak with ICON experts at booth 222 to learn how our experience across 180+ vaccine studies, end‑to‑end product development expertise, and fully integrated vaccine‑de...

How is AI transforming vaccine‑trial execution? On 31 March at 11:40 am at the World Vaccine Congress, join our interactive working group session, “Vaccine trials: How AI shifts execution from static plans to living sys...

Rare autoimmune diseases can leave patients particularly vulnerable to infection, but they often require unique considerations for vaccination. Learn what makes these cases so unique, and what to take into account when b...

Join ICON’s Dr. Anne Behringer on 25 March at 03:00 for a virtual presentation on “Cross-Border Recruitment in Clinical Trials: A Perspective on Operational Reality”. Learn more https://ow.ly/o25L50Yr8W3

The type of immunosuppressive treatment a patient with a rare autoimmune condition receives may impact how they respond to vaccines. Read our new article to explore this and other factors that can help determine the best...